The federal contract award SPE2DB22D9316|SPE2DB25FYM60, valued at $5,158.18, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the product "TYSABRI 300 MG/15 ML VIAL 15ML" and has an ultimate completion date of December 6, 2024. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide. This contract is not associated with a specific set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains. Additionally, DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical products to support the medical supply needs of Department of Defense healthcare sites.
Generated 2/13/25, 9:03 AM